Giant Cell Neoplasm — Variants & evidence

Giant Cell Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

4 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items (4 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CSF1 Overexpression1
Pexidartinib	Tenosynovial Giant Cell Tumor	Predictive	B	Supports Sensitivity Response	3	submitted	EID1969 23 patients were enrolled in the phase 2 extension study. The chosen phase 2 dose of PLX3397 was 1000 mg per day. 12/23 patients with tenosynovial giant-cell tumors had a partial response and 7 patien… (full text at CIViC) PMID 26222558 · Tap et al., 2015 · Open in CIViC	civic
H3-3A G35W3
(diagnostic)	Giant Cell Tumor of BoneALIAS	Diagnostic	B	Supports Positive	4	accepted	EID6469 In this study, the authors analyzed 53 cases of giant cell tumour of bone using capillary sequencing and massively parallel sequencing. They identified histone 3.3 mutations in 49/53 cases (92%). All … (full text at CIViC) PMID 24162739 · Behjati et al., 2013 · Open in CIViC	civic
〃	Giant Cell Tumor of BoneALIAS	Diagnostic	B	Supports Positive	4	accepted	EID12749 In this 2015 study, formalin-fixed paraffin-embedded (FFPE) tissue samples were retrieved from the diagnostic pathology archives of the Royal National Orthopaedic Hospital (RNOH) and the Basel Bone Tu… (full text at CIViC) PMID 27499898 · Presneau et al., 2015 · Open in CIViC	civic
〃	Giant Cell Tumor of BoneALIAS

Data updated 9 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.